LevyRAGonzalez-RiveraTKhamashtaM, et al.10 years of belimumab experience: what have we learnt?Lupus2021; 30: 1705–1721.
2.
TanakaYBassDChuM, et al.Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a phase 3 randomized placebo-controlled trial. Mod Rheumatol2019; 29: 452–460.
3.
FurieRRovinBHHoussiauF, et al.Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med2020; 383: 1117–1128.
4.
YuXChenNXueJ, et al.Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population. Am J Kidney Dis2023; 81: 294–306.e1.
5.
FanouriakisAKostopoulouMAlunnoA, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78: 736–745.
6.
BrunnerHIAbud-MendozaCViolaDOPaediatric Rheumatology International Trials Organisation PRINTO and the Pediatric Rheumatology Collaborative Study Group PRCSG, et al.Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis2020; 79: 1340–1348.
7.
RobertsJEBurnCSadunRE, et al.Real-world use and outcomes of belimumab in childhood-onset lupus: a single-center retrospective study. Lupus2023; 32: 1111–1116.
8.
MargiottaDPEBastaFBataniV, et al.Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. BMC Nephrol2018; 19: 54.
